SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) September 2, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Four orders of the Diasensor 1000 were sold to
Diasense distributor EuroSurgical Ltd. to fill orders in the
United Kingdom. The Diasensor is priced for European sale at
US$9000. In cooperation with Diasense, Biocontrol personnel
recently traveled to the UK to participate in the first device
sales and to begin to educate and establish a network of
clinicians, health care professionals, and diabetic associations
in the UK.
Item 6. Resignation of Registrant's Directors.
Not Applicable.
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
<PAGE>
DATED: September 2, 1998
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL SUBSIDIARY, DIASENSE, INC., SELLS FIRST DIASENSORS
Pittsburgh, PA - September 2, 1998 - Biocontrol Technology,
Inc. (Nasdaq:BICO) subsidiary Diasense, Inc. today announced that
four orders for the Diasensor(R)IOOO have already been received.
Two of the devices have been delivered to the teenagers who will
use the world's first noninvasive glucose sensors, and two will
soon be on their way to help other diabetics.
The devices, which recently received European marketing
approval (indicated by the CE Mark), were sold to Diasense
distributor EuroSurgical Ltd. to fill orders in the United
Kingdom, the first market opened for the Diasensor. The
Diasensor is priced for European sale at US$9,000.
In cooperation with Diasense, Biocontrol personnel recently
traveled to the UK to participate in the first device sales and
to begin to educate and establish a network of clinicians, health
care professionals, and diabetic associations in the UK.
EuroSurgical Director, George Cranstone, and Dr. Patrick Cooper,
of Biocontrol, presented clinical data from the CE Mark clinical
trial and discussed the use of the Diasensor at The Royal Free
Hospital in London, the UK Medical Device Agency, and the British
Diabetic Association. Although no approval other than the CE
Mark is needed to market the Diasensor in the 15-member European
Union, these groups were visited at their request to begin the
process of information dissemination on this leading edge
noninvasive technology.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
Also located in Pittsburgh, PA, Diasense is a subsidiary of
Biocontrol Technology and owns the patent, marketing and
distribution rights to the sensor. Biocontrol has the exclusive
rights to the research and development and manufacturing of the
Sensor.
This press release contains forward looking statements and
shareholders and potential investors are cautioned that such
statements are predictions and actual events or results may
vary significantly.
